ionispharma.com - Multiplikator EV/Sales IONS

The complexity of developing drugs for the heart and brain is evident in the price-to-sales multiple dynamics, where the metric stands at 5024.74. Ionis Pharmaceuticals (IONS) minimizes risks through alliances with industry behemoths. The asset's stability is guaranteed by the non-cyclical nature of biotech and its independence from macroeconomic factors. Growing demand for orphan drugs is expanding sales markets, ensuring the long-term resilience of the business.
Rincian metrik keuangan lan pasar Ionis (IONS)

For the non-cyclical genetic engineering business of Ionis Pharmaceuticals (IONS), this indicator determines the real value of assets by combining market capitalization and net debt, divided by annual sales volume. By analyzing the enterprise value-to-revenue ratio, an investor identifies discrepancies in the market price relative to stable royalty streams. Current price action for the enterprise value-to-revenue ratio confirms the company's high resilience to market shocks.